The links from this page take you to other government web sites. Once you leave this page, click the back button on your browser to return to DDMAC's web site.
The following links go to the FDA web site.
Chapter II - Definitions (Sec. 201  (g)(1), (k), (m), (n), & (p))
Chapter III - Prohibited Acts and Penalties (Secs. 301 , 302 , 303 , & 304 )
Chapter V - Drugs and Devices (Sec. 502.  (a), (e), (f), & (n))
The following links go to the Government Printing Office web site.
21 CFR 99 - Dissemination of Information on Unapproved/New Uses for Marketed Drugs, Biologics, and Devices
21 CFR 200 - General (Secs. 5, 7, & 200)
21 CFR 201 - Labeling Secs. 10, 100, & 200)
21 CFR 202 - Prescription Drug Advertising
21 CFR 312 - Investigational New Drug Application (Sec. 7)
21 CFR 314 - Applications to Market New Drug or Antibiotic (Secs. 81, 550, & 560)
Accelerated Approval Products: Submission of Promotional Materials *DRAFT* (Posted 3/26/1999)
Aerosol Steroid Product Safety Information in Prescription Drug Advertising and Promotional Labeling *FINAL* (Issued 12/1997, Posted 1/12/1998)
Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling *DRAFT* (Issued 1/1999, Posted 3/12/1999)
Promoting Medical Products in a Changing Healthcare Environment; I. Medical Product Promotion by Healthcare Organizations or Pharmacy Management Companies (PBMs) *DRAFT* (Issued 12/1997. Posted 1/5/1998) Reopening of Comment Period